After the multiple myeloma CAR-T therapy approval, eyes will now be on the FDAs decision regarding Opdivos use for additional indications, as well as Zeposia in ulcerative colitis. Abecma was being developed by Bristol Myers Squibb and bluebird bio Inc. CAR-T therapy refers to extraction of a patients own T cells, which are then genetically modified and infused back into the patients body. Crown Crafts Inc designs, markets and distributes infant, toddler and juvenile consumer products. That said, the recent approval marks the only approved CAR-T therapy for the treatment of multiple myeloma. These T-Cells target and destroy any abnormal cells, including cancer cells.
This is the first FDA approval for Opdivos use to date.
( z0 approve :ARG0 ( z1 government-organization :name ( z2 name :op "FDA" ) ) :ARG1 ( z3 this ) :ARG2 ( z4 use :ARG1 ( z5 product :name ( z6 name :op "Opdivos" ) ) ) :ord ( z7 ordinal-entity :value 1 ) :time ( z8 to-date ) )
(z0 / approve-01
    :ARG0 (z1 / government-organization
              :name (z2 / name
                        :op1 "FDA"))
    :ARG1 (z3 / this)
    :ARG2 (z4 / use-01
              :ARG1 (z5 / product
                        :name (z6 / name
                                  :op1 "Opdivos")))
    :ord (z7 / ordinal-entity
             :value 1)
    :time (z8 / to-date))
This is the first FDA approval for Opdivos use to date .
z7 :value 0
z1 :name z2
z2 :op1 1
z0 :ARG0 z1
z0 :ord z7
z0 :ARG1 z3
z5 :name z6
z6 :op1 2
z4 :ARG1 z5
z0 :ARG2 z4
z0 :time z8